Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Eriksson

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Thrombosis and Haemostasis|March 6, 2015
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancerSam Schulman, Samuel Z Goldhaber, Clive Kearon, et al.
BMC Public Health|December 25, 2012
Effects of self-rated health on sick leave, disability pension, hospital admissions and mortality. A population-based longitudinal study of nearly 15,000 observations among Swedish women and menChristina Halford, Thorne Wallman, Lennart Welin, et al.
The New England Journal of Medicine|December 8, 2009
Dabigatran versus warfarin in the treatment of acute venous thromboembolismSam Schulman, Clive Kearon, Ajay K Kakkar, et al.
Journal of Thrombosis and Thrombolysis|February 18, 2017
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER<sup>®</sup>, RE-COVER™ II, and RE-MEDY™Martin Feuring, Sam Schulman, Henry Eriksson, et al.
BMC Public Health|December 10, 2008
Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-aged men and women in Gothenburg, SwedenLennart Welin, Annika Adlerberth, Kenneth Caidahl, et al.
International Journal of Cardiology|December 10, 2013
Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923Zacharias Mandalenakis, Henry Eriksson, Lennart Welin, et al.
The New England Journal of Medicine|February 22, 2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolismSam Schulman, Clive Kearon, Ajay K Kakkar, et al.
Thrombosis and Haemostasis|September 26, 2015
Bleeding events with dabigatran or warfarin in patients with venous thromboembolismAmmar Majeed, Samuel Z Goldhaber, Ajay Kakkar, et al.
Circulation|December 18, 2013
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysisSam Schulman, Ajay K Kakkar, Samuel Z Goldhaber, et al.
JAMA|February 11, 2005
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trialJean-Noel Fiessinger, Menno V Huisman, Bruce L Davidson, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Thrombosis and Haemostasis|March 6, 2015
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancerSam Schulman, Samuel Z Goldhaber, Clive Kearon, et al.
BMC Public Health|December 25, 2012
Effects of self-rated health on sick leave, disability pension, hospital admissions and mortality. A population-based longitudinal study of nearly 15,000 observations among Swedish women and menChristina Halford, Thorne Wallman, Lennart Welin, et al.
The New England Journal of Medicine|December 8, 2009
Dabigatran versus warfarin in the treatment of acute venous thromboembolismSam Schulman, Clive Kearon, Ajay K Kakkar, et al.
Journal of Thrombosis and Thrombolysis|February 18, 2017
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER<sup>®</sup>, RE-COVER™ II, and RE-MEDY™Martin Feuring, Sam Schulman, Henry Eriksson, et al.
BMC Public Health|December 10, 2008
Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-aged men and women in Gothenburg, SwedenLennart Welin, Annika Adlerberth, Kenneth Caidahl, et al.
International Journal of Cardiology|December 10, 2013
Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923Zacharias Mandalenakis, Henry Eriksson, Lennart Welin, et al.
The New England Journal of Medicine|February 22, 2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolismSam Schulman, Clive Kearon, Ajay K Kakkar, et al.
Thrombosis and Haemostasis|September 26, 2015
Bleeding events with dabigatran or warfarin in patients with venous thromboembolismAmmar Majeed, Samuel Z Goldhaber, Ajay Kakkar, et al.
Circulation|December 18, 2013
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysisSam Schulman, Ajay K Kakkar, Samuel Z Goldhaber, et al.
JAMA|February 11, 2005
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trialJean-Noel Fiessinger, Menno V Huisman, Bruce L Davidson, et al.
Pageof 4